A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use
  • Acronyms PEXIUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 15 Feb 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0649).
    • 15 Feb 2013 Planned number of patients 350 added as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top